Yes I agree on the long term CSL will do well with $1B R&D budget. But on the short term with this uncertainty on their revenue, I doubt investors will be paying high PE multiple. CSL will have to demonstrate some visible potential products which are almost ready for the market or Vifor & Vaccine business come up with compensating increase in revenue. I think that is there issue at the moment.
Yes I agree on the long term CSL will do well with $1B R&D...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$308.05 |
Change
2.510(0.82%) |
Mkt cap ! $148.8B | |||
| Open | High | Low | Value | Volume |
| $307.94 | $309.48 | $306.35 | $254.8M | 840.3K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 268 | $307.92 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $308.23 | 139 | 2 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |